Text Size

Cabergoline Effect on Blood Sugar in Type 2 Diabetics

This study is not yet open for participant recruitment.
Verified October 2011 by Mashhad University of Medical Sciences
Sponsor:
Information provided by (Responsible Party):
Haleh Rokni Yazdi, Mashhad University of Medical Sciences
ClinicalTrials.gov Identifier:
NCT01459601
First received: October 24, 2011
Last updated: NA
Last verified: October 2011
History: No changes posted
  Purpose

Diabetic patients with poorly control blood sugar are prescribed cabergoline for 1 months and their blood glucose is evaluated.


Condition Intervention
Diabetes Type 2
 Drug: Cabergoline

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Single Blind (Subject)
Primary Purpose: Treatment
Official Title: Cabergoline Effects on Blood Sugar Control in Type 2 Diabetics

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Mashhad University of Medical Sciences:

Primary Outcome Measures:
  • FBS (fasting blood sugar) [ Time Frame: 30days ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • HbA1C [ Time Frame: 30days ] [ Designated as safety issue: No ]

Estimated Enrollment: 10
Study Start Date: January 2012
Estimated Study Completion Date: February 2012
Estimated Primary Completion Date: February 2012 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Cabergoline
    0,5mg per week
    Other Name: Dastinex
  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Type 2 diabetes
  • HbA1C>7

Exclusion Criteria:

  • HbA1C>10
  • Psychiatric disorders
  Contacts and Locations
No Contacts or Locations Provided
  More Information

No publications provided

Responsible Party: Haleh Rokni Yazdi, assisstant professor, Mashhad University of Medical Sciences
ClinicalTrials.gov Identifier: NCT01459601     History of Changes
Other Study ID Numbers: CabergolinDM
Study First Received: October 24, 2011
Last Updated: October 24, 2011
Health Authority: Iran: Ethics Committee

Keywords provided by Mashhad University of Medical Sciences:
diabetes mellitus
FBS
HbA1C
Cabergoline

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Cabergoline
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions
 Antiparkinson Agents
Anti-Dyskinesia Agents
Central Nervous System Agents
Dopamine Agonists
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on May 16, 2013